/

Coherus BioSciences, Inc.

CHRS US

CHRS USCoherus BioSciences, Inc.

United States Composite

2.16

USD

-0.05

(-2.26%)

-2.53EPS Dil.

-0.85P/E

242.38MMarket Cap

Next Earnings

May 6

Held by Insiders

1.35%

Held by Institutions

78.05%

Short % of Float

21.73%

YTD Yield

-71.83%

3Y Yield

-84.57%

5Y Yield

-85.29%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

472

473

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

109

112

Market Capitalization

403

408

374

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

385

444

476

Cash, Cash Equivalents & STI

145

131

118

Accounts Receivable, Net

141

217

261

Inventories

Total Current Liabilities

169

240

332

Payables & Accruals

151

217

308

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

21.80%

Net Income, GAAP

-64.67%

-79.41%

18.49%

Free Cash Flow

-53.76%

29.80%

27.98%

Total Cash Common Dividend

- -

Total Equity

-145.15%

-109.48%

-40.88%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

327

2022

211

2023

257

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-2.37

-0.40

-0.49

-0.60

-3.81

2022

-1.24

-0.65

-1.11

-0.76

-3.76

2023

-0.96

-0.49

-0.41

-0.71

-2.53

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Dennis M. Lanfear
Full Time Employees: 306
Sector: Healthcare
Industry: Biotechnology
Address: 333 Twin Dolphin Drive Redwood City CA United States 94065
CIK: 0001512762
Website: www.coherus.com
Business: Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Company News

Tipranks
a month ago
Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth
Yahoo
a month ago
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Yahoo
a month ago
Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
Tipranks
a month ago
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
FOOL
a month ago
Why Coherus Biosciences Stock Tumbled on Thursday
Yahoo
a month ago
Q4 2023 Coherus BioSciences Inc Earnings Call
Tipranks
a month ago
Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring
Yahoo
a month ago
Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...
Yahoo
a month ago
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Tipranks
a month ago
Options Volatility and Implied Earnings Moves Today, March 13, 2024
Yahoo
a month ago
In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions
Yahoo
a month ago
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Company Description

CEO: Mr. Dennis M. Lanfear
Full Time Employees: 306
Sector: Healthcare
Industry: Biotechnology
Address: 333 Twin Dolphin Drive Redwood City CA United States 94065
CIK: 0001512762
Website: www.coherus.com
Business: Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Company News

Tipranks
a month ago
Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth
Yahoo
a month ago
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Yahoo
a month ago
Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
Tipranks
a month ago
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
FOOL
a month ago
Why Coherus Biosciences Stock Tumbled on Thursday
Yahoo
a month ago
Q4 2023 Coherus BioSciences Inc Earnings Call
Tipranks
a month ago
Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring
Yahoo
a month ago
Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...
Yahoo
a month ago
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Tipranks
a month ago
Options Volatility and Implied Earnings Moves Today, March 13, 2024
Yahoo
a month ago
In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions
Yahoo
a month ago
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024